Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Price
Data
About
Competitors
Tokenization
Crypto
FAQ
Amgen Inc. stock logo

Amgen Inc.

AMGN·NASDAQ
Insights
Calculator
News

AMGN stock price change

On the last trading day, AMGN stock closed at 384.32 USD, with a price change of 4.49% for the day.
Trade stock futures
About Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more

AMGN key data

Previous close384.32 USD
Market cap206.95B USD
Volume3.84M
P/E ratio27.01
Dividend yield (TTM)2.48%
Dividend amount2.38 USD
Last ex-dividend dateNov 21, 2025
Last payment dateDec 12, 2025
EPS diluted (TTM)14.23 USD
Net income (FY)4.09B USD
Revenue (FY)33.23B USD
Next report dateFeb 3, 2026
EPS estimate4.730 USD
Revenue estimate9.47B USD
Shares float537.46M
Beta (1Y)0.22
Tokenized stocks

Have you heard of tokenized stocks?

A new way to trade stocks — anytime, anywhere, 24/7.

Learn more

Amgen Inc. overview

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Sector
Health technology
Industry
Biotechnology
CEO
Robert A. Bradway
Headquarters
Thousand Oaks
Website
amgen.com
Founded
1980
Employees (FY)
28K
Change (1Y)
+1.3K +4.87%
Revenue / Employee (1Y)
1.19M USD
Net income / Employee (1Y)
146.07K USD

AMGN Pulse

AI-generated updates on AMGN stock prices, capital flows, and market-moving news. Always DYOR.

• AMGN Stock Price 24h change: +4.49%. From 367.80 USD to 384.32 USD. The surge was driven by a fourth-quarter "beat and raise" earnings report and positive Phase 2 trial data for its obesity drug, MariTide.
• Technical Indicators: RSI (14) is at 69.00 (approaching overbought), MACD is 5.77 (Sell), and the 200-day SMA is 299.20 (Buy). The stock is in a strong short-term uptrend, having broken out of an ascending triangle, but may face resistance near its all-time high of $385.
• Amgen reported Q4 2025 revenue of $9.87 billion, exceeding the $9.47 billion estimate, and raised its 2026 revenue guidance to a range of $37 billion to $38.4 billion.
• Clinical data for MariTide showed up to 20% weight loss over 52 weeks with monthly or quarterly dosing, positioning it as a significant competitor in the obesity market.
• Goldman Sachs raised its price target for AMGN to $415 from $403, maintaining a "Buy" rating based on strong portfolio momentum and the obesity drug pipeline.
• The U.S. FDA launched the "PreCheck" pilot program to accelerate the construction and review of domestic drug manufacturing facilities to strengthen the medical supply chain.
• Pfizer and Merck released Q4 earnings highlighting a strategic focus on oncology and obesity, while the sector saw increased M&A activity interest in AI-focused biotech firms.
See more
about 21h ago
See more
about 1D ago

With just a Bitget account, you can trade stocks and cryptocurrencies at the same time.

Join now!

FAQ

What is the stock price of Amgen Inc.?

AMGN is currently priced at 384.32 USD — its price has changed by 4.49% over the past 24 hours. You can track the stock price performance of Amgen Inc. more closely on the price chart at the top of this page.

What is the stock ticker of Amgen Inc.?

Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ, Amgen Inc. is traded under the ticker AMGN.

What is the stock forecast of AMGN?

We've gathered analysts' opinions on Amgen Inc.'s future price. According to their forecasts, AMGN has a maximum estimate of 3843.20 USD and a minimum estimate of 768.64 USD.

What is the market cap of Amgen Inc.?

Amgen Inc. has a market capitalization of 206.95B USD.
NASDAQ/
AMGN